stoxline Quote Chart Rank Option Currency Glossary
  
Cullinan Oncology, Inc. (CGEM)
17.04  -0.69 (-3.89%)    03-28 16:00
Open: 17.79
High: 17.79
Volume: 372,022
  
Pre. Close: 17.73
Low: 17.02
Market Cap: 734(M)
Technical analysis
2024-03-28 4:50:24 PM
Short term     
Mid term     
Targets 6-month :  20.64 1-year :  22.58
Resists First :  17.67 Second :  19.34
Pivot price 16.49
Supports First :  14.97 Second :  12.46
MAs MA(5) :  17.01 MA(20) :  16.81
MA(100) :  12.91 MA(250) :  11.3
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  72.6 D(3) :  60.7
RSI RSI(14): 52.9
52-week High :  19.68 Low :  7.63
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CGEM ] has closed below upper band by 29.3%. Bollinger Bands are 16% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.82 - 17.91 17.91 - 17.98
Low: 16.82 - 16.91 16.91 - 16.99
Close: 16.9 - 17.05 17.05 - 17.17
Company Description

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 29 Mar 2024
Citigroup Inc. Raises Stake in Cullinan Oncology, Inc. (NASDAQ:CGEM) - Defense World

Fri, 22 Mar 2024
Cullinan Oncology, Inc. (NASDAQ:CGEM) Holdings Lifted by Exchange Traded Concepts LLC - Defense World

Mon, 18 Mar 2024
Cullinan Oncology, Inc. (NASDAQ:CGEM) Forecasted to Earn Q2 2024 Earnings of ($0.98) Per Share - MarketBeat

Fri, 15 Mar 2024
Is Cullinan Oncology Inc (CGEM) a Winner in the Healthcare Sector? - InvestorsObserver

Fri, 15 Mar 2024
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation - Yahoo Finance

Thu, 14 Mar 2024
Cullinan Oncology Inc reports results for the quarter ended in December - Earnings Summary - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 43 (M)
Shares Float 26 (M)
Held by Insiders 7.1 (%)
Held by Institutions 94.6 (%)
Shares Short 694 (K)
Shares Short P.Month 1,470 (K)
Stock Financials
EPS -3.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.57
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -22.8 %
Return on Equity (ttm) -31.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -134 (M)
Levered Free Cash Flow -89 (M)
Stock Valuations
PE Ratio -4.62
PEG Ratio 0
Price to Book value 1.61
Price to Sales 0
Price to Cash Flow -5.47
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android